Local ablative therapy vs. systemic therapy for patients with oligometastatic disease

Joachim Widder, MD, PhD, Medical University of Vienna & Vienna General Hospital, Vienna, Austria, discusses the use of local ablative therapies (LAT) for the treatment of patients with oligometastatic disease in solid tumors. Dr Widder takes us through some of the different considerations when using LAT compared to systemic treatment, such as what would be a suitable intermediate endpoint. This interview took place at the European Society for Radiotherapy and Oncology (ESTRO) 2022 annual congress in Copenhagen, Denmark, and online.
Be the first to comment